Skip to main content
BBIO
NASDAQ Life Sciences

Q3 Revenue Triples to $353M as Attruby Climbs; Three PDUFA Dates in Seven Months

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$70.665
Mkt Cap
$13.815B
52W Low
$60.22
52W High
$93.415
52W Position info
17% above low
Off High info
24% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

BBIO sits 17% above its 52-week low of $60.22.

Summary

BridgeBio posted Q3 2026 total revenues of $353.2 million versus $120.7 million a year ago, with U.S. Attruby net product revenue of $253.2 million — up roughly $31 million sequentially and $145 million year over year. The quarter included a one-time $75.0 million BEYONTTRA sales milestone from Bayer, and the operating loss narrowed to $11.6 million from $145.2 million a year earlier, while net income was a loss of USD -60.496 million. Cash and marketable securities stood at $1.5 billion as of September 30, which management says fully funds all three launches and expansion indications. The setup into year-end is the regulatory calendar: BBP-418 for LGMD2I/R9 has a November 27, 2026 PDUFA date, oral infigratinib for achondroplasia February 4, 2027, and encaleret for ADH1 May 8, 2027 — all under Priority Review, with field teams staffed. Also new this quarter: first participant dosed in the RECLAIM-HP Phase 3 for encaleret in chronic hypoparathyroidism (topline early 2028) and BBP-717 nominated as a development candidate for ATTR-CM with an IND planned for 2027. Attruby growth is coming from treatment-naïve starts, and the company keeps stacking real-world comparative data against tafamidis. Next hard catalyst is the BBP-418 FDA decision on November 27.

At the time of this announcement, BBIO was trading at $70.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.8B. The 52-week trading range was $60.22 to $93.42. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

BBIO - Latest Insights

BBIO
Oct 29, 2026, 4:52 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $70.69
Real-time Price: $78.29 info
Change: +$7.59 (+11%) info
Market Cap: $15.25B info
BBIO
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $71.44
Real-time Price: $78.29 info
Change: +$6.84 (+10%) info
Market Cap: $15.25B info
BBIO
Oct 13, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $65.75
Real-time Price: $78.29 info
Change: +$12.53 (+19%) info
Market Cap: $15.25B info
BBIO
Oct 11, 2026, 2:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $65.35
Real-time Price: $78.29 info
Change: +$12.94 (+20%) info
Market Cap: $15.25B info
BBIO
Oct 11, 2026, 11:42 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $65.35
Real-time Price: $78.29 info
Change: +$12.94 (+20%) info
Market Cap: $15.25B info